Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cavosonstat + Lumacaftor/Ivacaftor in CF (SNO-6)
NCT02589236Phase 2Completed
- Sponsor
- Nivalis Therapeutics
- Start
- Nov 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cavosonstat in cystic fibrosis (CF) (3 arms), sponsored by Nivalis Therapeutics. Primary endpoint: Absolute change from baseline in percent predicted FEV1 at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
cavosonstat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02589236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589236.